Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Blood|February 20, 2014
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractorinessMonica Messina, Ilaria Del Giudice, Hossein Khiabanian, et al.
Nature|March 11, 2011
Inactivating mutations of acetyltransferase genes in B-cell lymphomaLaura Pasqualucci, David Dominguez-Sola, Annalisa Chiarenza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 8, 2023
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung CancerKavya Ramkumar, Azusa Tanimoto, Carminia M Della Corte, et al.
Molecular Biology and Evolution|December 15, 2025
Coexisting With Humans: Genomic and Behavioral Consequences in a Small and Isolated Bear PopulationGiulia Fabbri, Roberto Biello, Maëva Gabrielli, et al.
Molecular Cancer|December 2, 2025
Multi-omic profiling provides insights into the heterogeneity, microenvironmental features, and biomarker landscape of small-cell lung cancerMingchao Xie, Miljenka Vuko, Shashank Saran, et al.
Molecular Cancer Therapeutics|July 24, 2023
First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and LymphomaErika P Hamilton, Judy S Wang, Amit M Oza, et al.
Blood|November 15, 2011
Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemiaDavide Rossi, Silvia Rasi, Giulia Fabbri, et al.
Blood|February 7, 2012
Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemiaDavide Rossi, Marco Fangazio, Silvia Rasi, et al.
The Journal of Experimental Medicine|June 15, 2011
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activationGiulia Fabbri, Silvia Rasi, Davide Rossi, et al.
British Journal of Cancer|April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerMelissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Pageof 5